Latest EMA approval: Yescarta in 2L DLBCL
In November 2022, Yescarta was approved in the EU for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Authorized treatment centers
Kite CAR T treatments are conducted in authorized treatment centres across Sweden
Watch webinar
View or review the exciting webinar with Professor Mats Jerkeman, Lunds universitet and professor Gunilla Enblad, Uppsala universitet.
YESCARTA® is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
YESCARTA® is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.
YESCARTA® is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Product information.
TECARTUS® is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton´s tyrosine kinase (BTK) inhibitor.
TECARTUS® is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractary B-cell precursor acute lymphoblastic leukaemia (ALL). Product information.
SE-TEC-0036 | 09/2024
